Targeted Genetics Expands Inflammation Trial
Posted on: Monday, 20 March 2006, 06:00 CST
Targeted Genetics has received approval from the FDA to amend the clinical protocol of its ongoing phase I trial of tgAAC94 in patients with inflammatory arthritis.
The amended protocol now includes a higher dose and increases the number of patients targeted for enrollment from 40 to 120. Under the amended protocol, the study is now designated a phase I/II trial.
Although the primary objective is safety, the increase in patient numbers and the exploration of additional secondary efficacy endpoints has warranted the trial designation upgrade from phase I to phase I/II.
"We are very excited about the progress we are making in our inflammatory arthritis program," said H Stewart Parker, president and CEO of Targeted Genetics. "The amended protocol allows us to obtain the data necessary to establish efficacy endpoints for additional clinical trials, determine a treatment effect and ultimately, lay the foundation for commercialization of the first gene therapeutic for rheumatoid arthritis."
Source: Datamonitor
Related Articles
- Calando Receives FDA Approval for Phase I Clinical Trial Using a Targeted siRNA Nanoparticle Therapeutic
- Targeted Genetics Announces Completion of Dosing for the Phase 1/2 Clinical Trial of tgAAC94 for Inflammatory Arthritis
- Gentium to Amend Protocol for Phase III Trial of Defibrotide
- Hana Biosciences Initiates Phase I Clinical Trial of a Targeted Chemotherapy Agent for Patients With Advanced Solid Tumors
- Encouraging Interim Results From a Phase I/II Trial of Targeted Genetics' tgAAC94 in Patients With Inflammatory Arthritis; Interim Data Show Positive Trends Toward Sustained Improvement in Signs and Symptoms of Disease
- Regeneron Completes Enrollment for IL-1 Trap Phase 3 Trial in Autoinflammatory Disease; Efficacy Phase of Trial on Target for Completion in 2006
- Lilly Launches Phase III Trial of Targeted Cancer Agent
- Array BioPharma Initiates Phase I Clinical Trial for Targeted Anticancer Drug ARRY-334543
- Surface Logix Phase I Clinical Trial Achieves Target Profile
- Targeted Genetics Announces Preliminary Results of Phase I Clinical Trial of tgAAC94 in Patients With Inflammatory Arthritis
 |
 |
User Comments (0)
RSS Feeds